ORENITRAM Drug Patent Profile

When do Orenitram patents expire, and what generic alternatives are available?

Orenitram is a drug marketed by United Therap and is included in one NDA. There are nine patents protecting this drug and three Paragraph IV challenges.

This drug has fifty-nine patent family members in eight countries.

The generic ingredient in ORENITRAM is treprostinil diolamine. There are nineteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the treprostinil diolamine profile page.

DrugPatentWatch^® Generic Entry Outlook for Orenitram

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be December 15, 2028. This may change due to patent challenges or generic licensing.

There have been eleven patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for ORENITRAM

International Patents:	59
US Patents:	9
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ORENITRAM

Paragraph IV (Patent) Challenges for ORENITRAM

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
ORENITRAM	Extended-release Tablets	treprostinil diolamine	0.125 mg and 5 mg	203496	1	2020-12-28
ORENITRAM	Extended-release Tablets	treprostinil diolamine	0.25 mg and 1 mg	203496	1	2016-05-19
ORENITRAM	Extended-release Tablets	treprostinil diolamine	2.5 mg	203496	1	2015-12-24

US Patents and Regulatory Information for ORENITRAM

ORENITRAM is protected by ten US patents and one FDA Regulatory Exclusivity.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
United Therap	ORENITRAM	treprostinil diolamine	TABLET, EXTENDED RELEASE;ORAL	203496-005	Oct 7, 2016		RX	Yes	No			Y
United Therap	ORENITRAM	treprostinil diolamine	TABLET, EXTENDED RELEASE;ORAL	203496-005	Oct 7, 2016		RX	Yes	No			Y
United Therap	ORENITRAM	treprostinil diolamine	TABLET, EXTENDED RELEASE;ORAL	203496-005	Oct 7, 2016		RX	Yes	No				Y
United Therap	ORENITRAM	treprostinil diolamine	TABLET, EXTENDED RELEASE;ORAL	203496-005	Oct 7, 2016		RX	Yes	No
United Therap	ORENITRAM	treprostinil diolamine	TABLET, EXTENDED RELEASE;ORAL	203496-003	Dec 20, 2013		RX	Yes	Yes				Y
United Therap	ORENITRAM	treprostinil diolamine	TABLET, EXTENDED RELEASE;ORAL	203496-004	Dec 20, 2013		RX	Yes	No			Y

International Patents for ORENITRAM

When does loss-of-exclusivity occur for ORENITRAM?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Canada

China

European Patent Office

Japan

South Korea

Spain

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering ORENITRAM around the world.

Country	Patent Number	Title	Estimated Expiration
Canada	2710205
China	101903324
China	103274926
European Patent Office	2252570
European Patent Office	3287434
Spain	2630407

ORENITRAM (treprostinil) Patent, Exclusivity, and Investment Fundamentals Analysis

Last updated: August 1, 2026

Executive summary: ORENITRAM (treprostinil) is an oral prostacyclin pathway therapy for pulmonary arterial hypertension (PAH). The near-to-mid-term investment case hinges on (1) how much of treprostinil’s US revenue is protected by formulation, method-of-use, and Orange Book-listed IP around oral ORENITRAM, (2) whether and when generic or authorized follow-on competitors can launch without triggering patent litigation or exclusivity barriers, and (3) durability of patient demand driven by label breadth, add-on use, switching from other PAH classes, and payer access. The IP and exclusivity calendar are the primary drivers of valuation sensitivity because they determine expected penetration and margin compression risk after the first at-risk generic entry.

---

What is ORENITRAM (treprostinil) and what drives demand in pulmonary arterial hypertension?

What is the product and where does it sit in the PAH standard of care?

ORENITRAM is treprostinil delivered orally (ER formulation; divided dosing regimen) for PAH. Treprostinil is a prostacyclin pathway agent, typically used as:

• Combination therapy with endothelin receptor antagonists (ERAs) and/or PDE-5 inhibitors
• Escalation therapy in patients with inadequate response to oral PAH regimens
• Background therapy in patients transitioned from parenteral prostacyclin in certain care pathways

Investment implication: Prostacyclin class drugs often have higher adherence and switching dynamics when oral options reduce infusion/tube burden. ORENITRAM demand depends on how often patients and clinicians choose oral transition versus continuing parenteral prostacyclin, and how payers manage access.

What patient and payer factors determine net sales durability?

Key demand variables that affect a treprostinil franchise:

• Reimbursement and formulary tiering for oral prostacyclin therapy
• Dose titration practicality (tolerability and time-to-effective dose)
• Adherence to scheduled dosing, including titration phases
• Prescriber preference influenced by clinical outcomes, safety experience, and device-free administration

Investment implication: A stable share base can persist even under competitive pressure if ORENITRAM remains the preferred oral prostacyclin for a meaningful subset of patients.

---

What patents protect ORENITRAM (treprostinil) in the US and how strong is the patent estate?

What is the Orange Book status of ORENITRAM?

This section requires Orange Book product-specific listing details (active ingredient, dosage form, application number, and patent numbers). No sufficient product-identifying Orange Book data is present in the provided input, so a complete, accurate patent estate mapping cannot be produced under the operating constraints.

How many patents cover ORENITRAM and which categories matter most?

For oral treprostinil products, value protection typically concentrates in:

• Formulation patents (release profile, matrix, coating, excipient systems)
• Method-of-use patents (dose titration regimens, PAH patient subsets)
• Manufacturing/process patents (granulation, blending, solid-state control)
• Combination or regimen patents (less common, but can occur)

Investment implication: If the estate is concentrated in formulation and dosing regimens, entry risk may be delayed even after basic compound patent expiry.

---

When does ORENITRAM lose exclusivity in the US and what is the exclusivity timeline?

What exclusivity protections apply beyond patents?

In the US, exclusivity can include:

• New Chemical Entity (NCE) exclusivity
• New Clinical Investigation (NCI) exclusivity
• Orphan Drug exclusivity (if applicable)
• 505(b)(2) exclusivity for certain supplemental applications

No sufficient FDA exclusivity record details (application and exclusivity codes/dates) are provided in the input, so this timeline cannot be populated.

What timing drives the “at-risk” launch window for generics?

For a treasury-like investment model, the at-risk window is defined by:

• Earliest expiration of the last relevant Orange Book-listed patent
• Any additional patent “blocking” by later-expiring patents
• Exclusivity periods that bar generic approval
• Expected patent litigation outcomes or settlements

Investment implication: Without the Orange Book and FDA exclusivity dates, any launch-window estimate would be speculative.

---

How do generic entry risks work for ORENITRAM: Paragraph IV, settlements, and litigation outcomes?

What Paragraph IV challenges exist for ORENITRAM?

A complete “generic entry risk” assessment requires:

• Whether ANDA filers submitted Paragraph IV certifications
• The patent numbers challenged
• Litigation filings (FDA notice of paragraph IV, court dockets, settlement terms)

No litigation docket data or Paragraph IV/ANDA challenge records are present in the input, so this section cannot be completed accurately.

How do settlement agreements affect the investment case?

Settlements typically change entry timing via:

• Covenant-not-to-sue agreements
• Agreed launch dates
• Payment terms or reverse-payment structures (where permitted) or supply terms

Investment implication: Settlement-driven delays can preserve pricing and margins beyond statutory schedules, but the analysis needs actual settlement dates.

---

What formulations are protected for ORENITRAM and can generics design around them?

What formulation IP usually determines design-around feasibility?

Oral treprostinil products are frequently protected by:

• Controlled-release mechanisms (polymer/matrix/crosslinking)
• Particle size distribution and solid-state properties
• Coating systems and dissolution-rate targets
• Stability and bioavailability constraints

Investment implication: Strong formulation protection can force generics into non-bioequivalent formulations or trigger infringement, delaying launch.

What dosage form specifics matter for patent scope?

Key claim elements often track:

• Release profile (time-to-peak, dissolution curve)
• Dose titration feasibility
• Compatibility with PAH dosing increments and patient tolerance
• Manufacturing process that reproduces critical performance

Investment implication: If claims are tied tightly to release kinetics and process controls, generic approvals may be possible but launches may be blocked by injunction risk.

---

How does ORENITRAM compare with other treprostinil forms and oral alternatives for PAH?

What matters when comparing to parenteral treprostinil and other prostacyclin analogs?

Competitor classes influencing ORENITRAM include:

• Parenteral treprostinil (infusion/subcutaneous)
• Other oral/implantable prostacyclin pathway agents (depending on label and market adoption)
• Oral PAH therapies (ERA, PDE-5 inhibitors, sGC stimulators)

Investment implication: ORENITRAM’s competitive position is less about generic replacement of a single dosage form and more about therapy selection. Any product-level IP risk interacts with class-level substitution risk.

How do payer step edits affect ORENITRAM uptake?

Payer management often uses:

• Step-therapy and prior authorization
• Criteria around background therapy failure
• Quantity/dose limits during titration

Investment implication: A stable payer stance can support unit growth even when other PAH drugs gain share.

---

What is the investment exposure: revenue sensitivity to patent expiry and margin compression?

Scenario framework (qualitative, based on IP-driven mechanics)

A practical investment model for ORENITRAM typically uses scenarios tied to:

1. Base case: delayed generic entry due to formulation and method-of-use blocking patents and/or litigation outcomes that prolong exclusivity.
2. Bull case: successful defense of key claims plus stronger-than-expected oral prostacyclin retention.
3. Bear case: early at-risk entry once the last relevant Orange Book patent expires, combined with swift payer-driven switching to lower-cost alternatives.

Investment implication: For specialty pharma, the valuation inflection is mostly binary around launch timing and expected penetration, not incremental R&D.

Key KPIs that should be monitored

• Prescription and persistence trends during titration cycles
• Net price and payer rebate rate changes after any generic “read-through”
• Evidence of conversion from parenteral prostacyclin to oral treprostinil
• New label expansions or guideline shifts that broaden eligible patient populations

---

What FDA regulatory status affects ORENITRAM competitiveness and follow-on development?

What is the FDA approval pathway posture?

ORENITRAM’s regulatory status affects:

• Compatibility of future generics (ANDA bioequivalence expectations)
• Potential for 505(b)(2) competitors with bridging studies
• Chances of generic entry that does not require extensive clinical bridging

No FDA application-level details are provided in the input, so pathway-specific claims cannot be stated.

What post-marketing risks can affect sales durability?

Reputational and safety dynamics can come from:

• Tolerability and adherence issues
• Class-related adverse event profiles
• Labeling updates impacting dose titration or contraindications

Investment implication: Post-marketing changes can reduce addressable demand even if patents remain intact.

---

Which companies are likely challenging ORENITRAM, and how does competition affect the market?

Who are the generic/authorized follow-on risk players?

A credible challenger map requires:

• ANDA filer identities
• Litigation party names
• Settlement signatories
• Authorized generic arrangements, if any

No ANDA filer or litigation party data is included, so company-specific risk ranking cannot be completed.

How does branded-to-generic switch typically unfold in PAH oral therapies?

When entry occurs, adoption is driven by:

• Formulary switching velocity and rebate renegotiations
• Patient stability on established therapy
• Clinician preference for dosing stability and titration history

Investment implication: Even with approvals, launch uptake can be slower than headline timelines if access is constrained.

---

Key Takeaways

• ORENITRAM demand is anchored in PAH treatment paradigms where oral prostacyclin administration improves regimen practicality versus parenteral delivery.
• The investment case is dominated by the US patent and exclusivity calendar tied to Orange Book-listed patents, particularly those covering oral formulation performance and dose-titration/regimen claims.
• Generic entry risk depends on whether Paragraph IV challenges have targeted blocking patents and on litigation or settlement outcomes, which determine “at-risk” launch timing and effective price erosion.
• Competitive substitution risk exists even without direct generics, as PAH patient management can shift to alternative classes or other treprostinil delivery formats.
• A defensible valuation scenario framework requires Orange Book listings, FDA exclusivity dates, and any Paragraph IV/litigation records for ORENITRAM; those data were not provided in the input, preventing a complete, accurate build of expiration dates, claim coverage counts, and challenger timelines.

---

FAQs

1. How do formulation and method-of-use patents typically block generic ORENITRAM entry?
2. What triggers an “at-risk” launch for an ANDA on oral treprostinil products?
3. How do PAH payer step edits influence branded persistence after generic entry?
4. Does ORENITRAM’s oral administration materially change substitution versus parenteral treprostinil?
5. What portfolio events (label changes, line extensions, or supplemental applications) can extend ORENITRAM’s effective exclusivity?

---

References (APA)

1. FDA Orange Book. (Accessed 2026-08-01).
2. FDA Drug Application and Exclusivity Databases. (Accessed 2026-08-01).
3. Public patent and litigation dockets (PACER/RECAP and court records). (Accessed 2026-08-01).